Phathom Pharmaceuticals, Inc. (PHAT)

8.47 -0.48 (-5.36%) At close: 04:00PM EST

Phathom Pharmaceuticals, Inc.

100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
https://www.phathompharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 112

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Terrie J. Curran	President, CEO & Director	1.11M	N/A	1969
Mr. David A. Socks	Co-Founder & Director	58.78k	N/A	1975
Dr. Azmi Nabulsi M.D., M.P.H.	Co-Founder & COO	815.21k	N/A	1960
Ms. Molly Henderson CPA, MBA	Chief Financial & Business Officer	671.27k	N/A	1971
Mr. Aditya Kohli Ph.D.	Co-Founder	319.65k	N/A	1988
Mr. Anthony J. Guzzo	Chief Accounting Officer	468.27k	N/A	1973
Mr. Joseph Hand J.D.	Chief Administrative Officer	N/A	N/A	N/A
Mr. Lawrence Miller Esq., J.D.	General Counsel & Secretary	N/A	N/A	N/A
Mr. Tom Harris	Chief Development Sciences Officer	N/A	N/A	N/A
Dr. Eckhard Leifke M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Corporate governance

Phathom Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.